<?xml version="1.0" encoding="UTF-8"?><faers xmlns="http://fda.gov/ns/faers"><meta><status>PENDING</status><version>v2</version><patient-age/><report-id>US-ELI_LILLY_AND_COMPANY-US201301004752</report-id><gender>female</gender><reactions><reaction>angioedema syndrome</reaction></reactions><drugs><drug><ndc>59572983</ndc><drug-name>HUMALOG LISPRO</drug-name><manufacturer/><ingredients/></drug></drugs><outcomes/><country>United States</country><geo/></meta><original><ichicsr lang="en" xmlns="">
	<ichicsrmessageheader>
		<messagetype>ichicsr</messagetype>
		<messageformatversion>2.1</messageformatversion>
		<messageformatrelease>2.0</messageformatrelease>
		<messagenumb>734882_111</messagenumb>
		<messagesenderidentifier>LILLYFDA</messagesenderidentifier>
		<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
		<messagedateformat>204</messagedateformat>
		<messagedate>20130125151007</messagedate>
	</ichicsrmessageheader>
	<safetyreport>
		<safetyreportversion>1</safetyreportversion>
		<safetyreportid>US-ELI_LILLY_AND_COMPANY-US201301004752</safetyreportid>
		<primarysourcecountry>US</primarysourcecountry>
		<occurcountry>US</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>2013-01-22</transmissiondate>
		<reporttype>1</reporttype>
		<serious code="1">Yes</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>2</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>1</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>2013-01-14</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>2013-01-14</receiptdate>
		<additionaldocument>2</additionaldocument>
		<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
		<companynumb>US-ELI_LILLY_AND_COMPANY-US201301004752</companynumb>
		<primarysource>
			<reportertitle>Dr</reportertitle>
			<reportergivename>Nadem</reportergivename>
			<reporterfamilyname>Sayegh</reporterfamilyname>
			<reporterstreet>655 Yonkers Ave</reporterstreet>
			<reportercity>Yonkers</reportercity>
			<reporterstate>NY</reporterstate>
			<reporterpostcode>10704</reporterpostcode>
			<reportercountry>US</reportercountry>
			<qualification code="1">Physician</qualification>
		</primarysource>
		<primarysource>
			<reporterfamilyname>Sanofi-Aventis</reporterfamilyname>
			<reporterstreet>Box 5925
55 Corporate Drive</reporterstreet>
			<reportercity>Breidgewater</reportercity>
			<reporterstate>NJ</reporterstate>
			<reporterpostcode>08807-5925</reporterpostcode>
			<reportercountry>US</reportercountry>
			<qualification code="5">Consumer or non-health professional</qualification>
		</primarysource>
		<sender>
			<sendertype>1</sendertype>
			<senderorganization>Eli Lilly and Company</senderorganization>
			<senderdepartment>BS200</senderdepartment>
			<sendertitle>Mr.</sendertitle>
			<sendergivename>John</sendergivename>
			<sendermiddlename>A.</sendermiddlename>
			<senderfamilyname>Fredenburg</senderfamilyname>
			<senderstreetaddress>Lilly Corporate Center</senderstreetaddress>
			<sendercity>Indianapolis</sendercity>
			<senderstate>IN</senderstate>
			<senderpostcode>46285</senderpostcode>
			<sendercountrycode>US</sendercountrycode>
			<sendertel>2770207</sendertel>
			<sendertelcountrycode>317</sendertelcountrycode>
			<senderfax>8666441697</senderfax>
		</sender>
		<receiver>
			<receivertype>2</receivertype>
			<receiverorganization>Food and Drug Administration - CDER</receiverorganization>
			<receiverdepartment>Office of Surveillance and Epidemiology</receiverdepartment>
			<receivertitle>Mr</receivertitle>
			<receivergivename>Roger</receivergivename>
			<receiverfamilyname>Goetsch</receiverfamilyname>
			<receiverstreetaddress>12300 TwinbrookParkway, Suite 240</receiverstreetaddress>
			<receivercity>Rockville</receivercity>
			<receiverstate>MD</receiverstate>
			<receiverpostcode>20851</receiverpostcode>
			<receivercountrycode>US</receivercountrycode>
			<receivertel>3017709299</receivertel>
			<receivertelcountrycode>001</receivertelcountrycode>
			<receiverfax>3017706614</receiverfax>
			<receiverfaxcountrycode>001</receiverfaxcountrycode>
			<receiveremailaddress>roger.goetsch@fda.hhs.gov</receiveremailaddress>
		</receiver>
		<patient>
			<patientsex code="2">Female</patientsex>
			<reaction>
				<primarysourcereaction>angioedema syndrome</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Angioedema</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Angioedema</reactionmeddrapt>
				<termhighlighted>4</termhighlighted>
				<reactionoutcome code="6">unknown</reactionoutcome>
			</reaction>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>HUMALOG LISPRO</medicinalproduct>
				<obtaindrugcountry>US</obtaindrugcountry>
				<drugauthorizationnumb>20-563</drugauthorizationnumb>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<drugauthorizationholder>Eli Lilly and Company</drugauthorizationholder>
				<drugdosagetext>UNK, unknown</drugdosagetext>
				<actiondrug code="5">Unknown</actiondrug>
				<activesubstance>
					<activesubstancename>INSULIN, LISPRO</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Angioedema</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not Reported</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Angioedema</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not Reported</drugresult>
				</drugreactionrelatedness>
			</drug>
			<summary>
				<narrativeincludeclinical>This spontaneous case, reported by a <Semaphore x="2398439" class="Occupation" value="Physician" score="1.00" ID="C25741">physician </Semaphore>via another <Semaphore x="2199623" class="Occupation" value="Manufacturer" score="1.00" ID="C25392">manufacturer </Semaphore>who <Semaphore x="1802982" class="Disease or Finding" value="Communication Disorder" score="1.00" ID="C2958">contacted </Semaphore>the company to report an <Semaphore x="2724216" class="MedDRA LLT" value="Adverse event" score="1.00" ID="10060933">adverse event</Semaphore>, <Semaphore x="1805433" class="Procedure" value="Concern About Finances" score="1.00" ID="C104604">concerns </Semaphore>a female patient of unknown age.Medical history and concomitant medications were not provided.The patient received <Semaphore x="730644" class="Medicine" value="Insulin Lispro" score="0.87" ID="290552"><Semaphore x="2809836" class="MedDRA LLT" value="Blood insulin" score="1.00" ID="10005605">insulin </Semaphore>lispro </Semaphore>(<Semaphore x="669768" class="Medicine" value="Humalog" score="0.49" ID="228096">Humalog</Semaphore>) at an unknown dose and formulation via an unknown device for an unspecified <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">treatment </Semaphore>beginning on an unknown date. On an unknown date, time to onset not provided, the patient experienced <Semaphore x="1525745" class="Disease or Finding" value="Angioedema" score="1.00" ID="C112175">angioedema </Semaphore><Semaphore x="2598340" class="Disease or Finding" value="Syndrome" score="1.00" ID="C28193">syndrome </Semaphore>and <Semaphore x="3071319" class="MedDRA LLT" value="Lip swelling" score="1.00" ID="10024570"><Semaphore x="2597501" class="Disease or Finding" value="Swelling" score="1.00" ID="C3399">swelling </Semaphore>of her <Semaphore x="2116170" class="AnatomicStructure" value="Lip" score="1.00" ID="C12220">lips </Semaphore></Semaphore>with <Semaphore x="730644" class="Medicine" value="Insulin Lispro" score="0.87" ID="290552"><Semaphore x="2809836" class="MedDRA LLT" value="Blood insulin" score="1.00" ID="10005605">insulin </Semaphore>lispro</Semaphore>. No further details were provided. The event of <Semaphore x="1525745" class="Disease or Finding" value="Angioedema" score="1.00" ID="C112175">angioedema </Semaphore><Semaphore x="2598340" class="Disease or Finding" value="Syndrome" score="1.00" ID="C28193">syndrome </Semaphore>was considered serious for other reasons by the company. The event <Semaphore x="2353201" class="Disease or Finding" value="Outcome" score="1.00" ID="C20200">outcome </Semaphore>and action taken with <Semaphore x="730644" class="Medicine" value="Insulin Lispro" score="0.87" ID="290552"><Semaphore x="2809836" class="MedDRA LLT" value="Blood insulin" score="1.00" ID="10005605">insulin </Semaphore>lispro </Semaphore>were not provided.The reporting <Semaphore x="2398439" class="Occupation" value="Physician" score="1.00" ID="C25741">physician </Semaphore>did not offer an opinion of relatedness.</narrativeincludeclinical>
			</summary>
		</patient>
	</safetyreport>
</ichicsr></original></faers>